Dentsply Sirona has announced that it has acquired Datum Dental, Ltd. with its strong OSSIX® biomaterial portfolio.
The acquisition of Datum Dental, an Israel-based company known for its innovative dental regeneration products with the clinically superior proprietary technology GLYMATRIX®, will open up significant opportunities for Dentsply Sirona within its implants segment.
With a track record of simplifying and developing innovations for regenerative procedures, the OSSIX® portfolio will support the vision to become one of the leaders in the dental regeneration industry.
With innovative products driven by the GLYMATRIX® core technology, OSSIX® bio-durable design will ensure long-term predictable and superior results. The OSSIX® dental regeneration products will support and enhance the future of implant dentistry and oral care.
“Datum Dental perfectly fits in our strategy to deliver innovative and meaningful solutions for our customers. The biomaterial sector is an important cornerstone of the future of dentistry. The acquisition is another important step for us to deliver on our purpose to empower dental professionals to provide patients with better dental care and make people smile,” said Gene Dorff, group vice president, Implants Product Group of Dentsply Sirona.
“We are pleased that the OSSIX® family is becoming part of the market leader in dental. Dentsply Sirona offers us opportunities to work on continued innovation with the strongest research and development team (R&D) in the industry. Our R&D pipeline will continue to develop new, safe and transformational solutions – that simplify procedures and overcome major deficiencies in existing biomaterial-based regenerative products,” said Itay Itzhaky, chief executive officer of Datum Dental.
Since 2016, Dentsply Sirona has already been in distribution agreements with Datum Dental. Today, Dentsply Sirona is promoting the full OSSIX® portfolio (OSSIX® Plus, OSSIX® Volumax, and OSSIX™ Bone) in the US, Canada, Colombia, France, Belgium, UK-Ireland, Nordics, Poland, Romania, Turkey, and Hong Kong.
Clinicians will benefit in the future from OSSIX® products’ being implemented in a broad set of solutions and workflows and Dentsply Sirona’s capacity to invest in the future development. The strong OSSIX® portfolio will be the foundation of the Regenerative portfolio of Dentsply Sirona.